Tofacitinib in Refractory Scleritis: A Case Series.

Area of Science:

• Ophthalmology
• Immunology
• Rheumatology

Background:

• Scleritis is a severe inflammatory eye condition often resistant to standard treatments.
• Systemic immunosuppressive agents are frequently used but may not be effective or tolerated by all patients.

Purpose of the Study:

• To evaluate tofacitinib as a steroid-sparing immunomodulatory therapy for refractory scleritis.
• To assess the efficacy and tolerability of tofacitinib in patients with scleritis unresponsive to conventional treatments.

Main Methods:

• Case series involving three patients with refractory scleritis.
• Treatment with tofacitinib, a Janus kinase inhibitor, as a steroid-sparing agent.

Main Results:

• Tofacitinib was used in three patients with refractory scleritis.
• Patients were either recalcitrant or intolerant to conventional therapies.

Conclusions:

• Tofacitinib demonstrates potential as a steroid-sparing immunomodulatory agent for refractory scleritis.
• Further research is warranted to confirm the efficacy and safety of tofacitinib in managing this condition.